AFC-HD AMS Life Science Co.,Ltd. Logo

AFC-HD AMS Life Science Co.,Ltd.

An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.

2927 | T

Overview

Corporate Details

ISIN(s):
JP3124700000
LEI:
Country:
Japan
Address:
静岡市駿河区豊田3丁目6番36号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer (OEM) specializing in health foods, dietary supplements, and cosmetics. Functioning as a holding company, it oversees a group of subsidiaries that manage the entire product value chain, from research and development to manufacturing and sales. The group's activities include direct mail order and wholesale distribution, the development and production of health-related media, and the manufacture of traditional Kampo medicines. The company leverages its integrated structure, including a dedicated R&D laboratory for product innovation and a GMP-certified manufacturing facility, to deliver a comprehensive range of quality products to its diverse customer base.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-15 08:30
Registration Form
有価証券届出書(組込方式)
Japanese 260.6 KB
2025-04-14 08:33
Regulatory News Service
確認書
Japanese 8.9 KB
2025-04-14 08:32
Interim Report
半期報告書-第45期(2024/09/01-2025/08/31)
Japanese 271.0 KB
2025-02-07 02:18
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.9 KB
2024-11-28 07:36
Post-Annual General Meeting Information
臨時報告書
Japanese 28.8 KB
2024-11-27 07:34
Governance Information
内部統制報告書-第44期(2023/09/01-2024/08/31)
Japanese 24.0 KB
2024-11-27 07:33
Registration Form
確認書
Japanese 8.9 KB
2024-11-27 07:32
Registration Form
有価証券報告書-第44期(2023/09/01-2024/08/31)
Japanese 1.2 MB
2024-11-21 03:12
Regulatory News Service
臨時報告書
Japanese 24.5 KB
2024-07-16 08:02
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-07-16 08:02
Quarterly Report
四半期報告書-第44期第3四半期(2024/03/01-2024/05/31)
Japanese 211.7 KB
2024-04-15 08:08
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-04-15 08:07
Quarterly Report
四半期報告書-第44期第2四半期(2023/12/01-2024/02/29)
Japanese 268.2 KB
2024-01-15 05:58
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-01-15 05:57
Quarterly Report
四半期報告書-第44期第1四半期(2023/09/01-2023/11/30)
Japanese 214.8 KB

Automate Your Workflow. Get a real-time feed of all AFC-HD AMS Life Science Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AFC-HD AMS Life Science Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AFC-HD AMS Life Science Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.